Vaccines and Immunological Agents

78 Drugs classified under this therapeutic system

Bacterial and Viral Vaccines. RSV F antigen, A+B subgroups 60+60 mcg/ 0.5 ml.
Powder and solv. for sol. for IM inject. (60+60 mcg/vial) 1/5/10 doses
A sgle. dose of 0.5 ml to be admin to pregn. women between weeks 24-36  and to persons aged >60. See lit.
• Pass. protect.against lower respir. tract dis. caused by respir. syncytial virus (RSV) in infants from birth through 6 mo. of age following maternal immunisat. during pregn. • Active immunisat. of 60 years of age and older for the prevent. of lower respir. tract disease caused by RSV.
C/I: Hypersens.

Haemophilus Influenzae type b 10 mcg / 0.5 ml.
VIALS: (pwdr.) 1 + syringe: 0.5 ml. I.M or
S.C. route. See lit.
Prevent. in inf. against invas. dis.
caused by H. influenza type B such as
meningit., septicem., cellulit., arthrit.,
epiglotit.
C/I: Hypersens., espec. tetanus protein.

Tetanus Toxoid 5 Lf, Diphtheria Toxoid 2 Lf, Pertussis Toxoid 2.5 mcg, Filamentous Haemagglutinin 5 mcg, Pertactin 3 mcg, Fimbriae Types 2+3 5 mcg.
VIAL: 1, 5 x 0.5 ml. Admin I.M. into
deltoid musc. See lit.
Active booster immunizat. against
diphth., tetanus and pertussis in ages
4-64 yrs.
C/I: Known system. hypersens. to any
compon. vaccine aft. prev. admin.
Encephalopathy not attributable to
another identifiable cause within 7 days of admin. prev. dose of any vaccine cont.
pertussis antigens (whole cell or
acellular). Progress. neurolog. disords.,
uncontroll. epilepsy, progress.
encephalopath. until tmt. regimen
established. Febrile or acute illness.

Diphtheria Toxoid Not less than 2 IU, Tetanus Immuneglobulin 5 Lf, Pertussis Toxoid 2.5 mcg, Filamentous Haemagglutinin 5 mcg, Fimbriae Types 2+3 5 mcg, Pertactin 3 mcg, Poliomyelitis Virus Type 1 40 D-antigen units, Poliomyelitis Virus Type 2 8 D-antigen units, Poliomyelitis Virus Type 3 32 D-antigen units.
PRE-FILLED SYRINGES (susp. for inject.):
1, 10, 20. Starting from age 3, a single
I.M. 0.5 ml dose, in deltoid muscle,
applies to all age groups.
Active booster immunisat. for prevent.
diphth., tetanus, pertussis and polio,
from 3 yrs and over.
C/I: Hypersens., anaphylact./allerg.
reacts. to similar vaccine,
encephalopath. of unknown origin
within 7 days of prev. immunisat. dose
of any vaccine cont. pertussis antigens
(whole cell or acellular). Progress.
neurolog. disords., uncontroll. epilepsy,
progress. encephalopath. until tmt.
regimen established. Febrile or acute
illness. See lit.

Respiratory Syncytial Virus (RSV) vaccine. Respiratory Syncytial Virus recombinant glycoprotein F antigen 120 mcg/ 0.5 ml.
Vial, Powder (163 mcg) and suspens. for IM inject. X1/X10
Sgle. dose of 0.5 ml.
Active immunisation for the prevent. of lower respirat. tract dis. (LRTD) caused by respirat. syncytial virus in adults 60 years of age and older.
C/I:Hypersens

Hepatitis A Virus Antigen (Inactivated) 80 U / 0.5 ml.
SUSP. FOR INJECT. (single dose prefilled
syringe): 1. Prim. vaccinat: 0.5 ml.
Booster within 6-8 mths. foll. initial dose.
I.M. in deltoid. See lit.
SUSP. FOR INJECT. (multidose vial): 10 x
0.5 ml. As above
Active immunizat. against hepatit. A
virus in child 12 mths-15 yrs (inclus.).
C/I: Hypersens. to active ingred.,
neomycin, polysorbate, foll. prev. inject.
Feber, acute/chron. evolv. dis. See lit.